On July 16th, 2019, Elpiscience Biopharmaceutical Ltd. (Elpiscience) announced the official opening of its Shanghai R&D Center. In less than two years since its inception, the company has established independent research and development and production platforms ranging from “target discovery”, “functional verification”, “multi-specific antibody construction” to “process optimization”. Elpiscience possesses a competitive pipeline, while also striving to collaborate and innovate with other world-class companies.
Elpiscience was privileged to host distinguished attendees including Chen Weiwei, deputy general manager of Zhangjiang (Group) Co., Ltd., Lou Qi, general manager of Zhangjiang Biomedical Base Development Co., Ltd., and representatives of biomedical enterprises, research institutes and investment institutions. The ceremony proceeded with inspiration speeches, laboratory tours, and gathering of industry experts.
‘Focus on science and create hope’. Elpiscience believes that the completion of Shanghai R&D Centre is an important milestone for its development. Elpiscience strives to advance the next-generation immunotherapeutics in order to benefit patients.